TICKERNERD
Menu
NAUTNAUTHealthcare · Biotechnology

NAUT Stock Forecast: Nautilus Biotechnology, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.95
+5.82% on the day

The 2 Wall Street analysts covering Nautilus Biotechnology, Inc. hold a median 12-month price target of $4 — +319.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$114.7M
Ticker Nerd rank
55 / 100
Median analyst target
$4.00
Analysts covering
2
Total return, dividends reinvested
1W
+7.0%
1M
−43.9%
YTD
−51.1%
1Y
+42.9%
From 52W high
−75.8%
From 52W low
+49.4%
$0.64
$3.95
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NAUT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Nautilus Biotechnology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
55 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
74
Size
74
Issuance
69
Accruals
59
Momentum
58
Revisions
57
Volatility
48
Value
20
Quality
18

Growth (74): Sales and profits are climbing, and climbing faster than before.

Quality (18): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NAUT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NAUT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Oct 25Jan 26Apr 26Jul 26NAUTHigh $4.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $4.00Median $4.00High $4.00

The green dot is the last close — the median target sits +319.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Feb 2026GuggenheimMaintainsBuy$2.50 → $4.00
5 Dec 2024Goldman SachsDowngradeSell—
27 June 2024GuggenheimInitiatesBuy—
3 June 2024JefferiesAssumesHold$5.00 → $3.00
3 Aug 2023Morgan StanleyReiteratesEqual-Weight—
3 Aug 2022Goldman SachsMaintainsNeutral—
3 Aug 2022Morgan StanleyMaintainsEqual-Weight—
14 July 2022Goldman SachsMaintainsNeutral—
13 Apr 2022Goldman SachsMaintainsNeutral—
6 Jan 2022Morgan StanleyInitiatesEqual-Weight—
2 Nov 2021Cowen & Co.InitiatesOutperform—
4 Aug 2021Goldman SachsInitiatesNeutral—
13 July 2021JefferiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NAUT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

NAUT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Nautilus Biotechnology, Inc. (NAUT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.9×

Cheaper than 85% of US stocks

Price / sales
607.9×

Cheaper than 2% of US stocks

Price / book
0.9×

Cheaper than 77% of US stocks

EV / EBITDA
−1.0×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
−50.0%

Higher than 2% of US stocks

Operating margin
−8296.3%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−36.2%

Higher than 25% of US stocks

Return on assets
−20.8%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NAUT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NAUTNautilus Biotechnology, Inc.$114.7M
55
HURATuHURA Biosciences, Inc.$121.4M
17
GNLXGenelux Corp.$121.6M
19
INOInovio Pharmaceuticals, Inc.$121.9M
44
RANIRani Therapeutics Holdings, Inc.$120.0M
64
GUTSFractyl Health, Inc.$123.7M
30
ANIXAnixa Biosciences, Inc.$124.4M
85

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Nautilus Biotechnology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NAUT news & analysis

Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullback

Seeking Alpha · 3 Aug 2026negative

Nautilus Biotechnology is shifting focus to targeted proteoform assays after broadscale testing failed to support its previous commercialization roadmap, and its path with Voyager is clearer though Early Access revenue remains too limited to demonstrate recurring sales. The company still faces risks from possible execution setbacks, ongoing cash burn, and a likely capital raise by 2027.

Why it matters — A NAUT watcher would care because the company's revised strategy, limited early revenue, cash burn, and likely capital raise could materially affect its commercial outlook and financial runway.

Nautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 28 July 2026neutral

Seeking Alpha published the transcript of Nautilus Biotechnology, Inc.'s Q2 2026 earnings call.

Why it matters — Earnings call transcripts provide direct insight into the company's financial results and management's commentary on performance.

Nautilus Biotechnology Q2 Earnings Call Highlights

MarketBeat · 28 July 2026neutral

Nautilus Biotechnology announced it is reallocating a significant portion of its R&D resources toward proteoform applications, driven by customer interest and a delay in its Broadscale broad-proteome program.

Why it matters — This shift in R&D focus signals a strategic pivot for Nautilus, potentially altering the timeline and scope of its core proteomics platform development.

Nautilus Biotechnology Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 28 July 2026positive

Nautilus Biotechnology reported financial results for the second quarter of 2026 and recognized its first revenue, including grant revenue from the Michael J. Fox Foundation.

Why it matters — This marks the company's first revenue milestone, indicating early commercial progress for its single-molecule proteome analysis platform.

FAQ

Frequently asked questions about NAUT stock

What is the NAUT stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Nautilus Biotechnology, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NAUT stock a buy right now?

Of the 2 analysts covering Nautilus Biotechnology, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nautilus Biotechnology, Inc. 55 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NAUT?

As at 22 Aug 2026, Nautilus Biotechnology, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (74 of 100).

Will NAUT stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +319.1% from the last close, and Ticker Nerd's factor model ranks Nautilus Biotechnology, Inc. 55 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NAUT stock forecast for 2030?

No analyst covering Nautilus Biotechnology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NAUT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has NAUT stock performed over the past year?

Nautilus Biotechnology, Inc. returned +42.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nautilus Biotechnology, Inc. do?

Nautilus Biotechnology, Inc. is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome.

What is the latest news on NAUT?

The most recent item we track (Seeking Alpha, 3 Aug 2026): "Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullback". Nautilus Biotechnology is shifting focus to targeted proteoform assays after broadscale testing failed to support its previous commercialization roadmap, and its path with Voyager is clearer though Early Access revenue remains too limited to demonstrate recurring sales. The company still faces risks from possible execution setbacks, ongoing cash burn, and a likely capital raise by 2027.

Company

About Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. Its core offering, the Nautilus Platform, provides an end-to-end proteomics solution that includes instruments, consumables, and software for analysis, enabling high-resolution optical imaging, fluidics, and liquid handling to process protein libraries and decode proteins in biological samples. The company has developed the Voyager Platform, a benchtop system supporting Iterative Mapping to analyze up to 10 billion intact proteins and proteoforms in a single run, along with specialized assays like tau proteoforms for neurodegenerative disease research and alpha-synuclein for Parkinson's biomarkers. Nautilus Biotechnology, Inc. runs an Early Access Program granting select researchers exclusive access, data interpretation support, and custom assay development, fostering collaborations with institutions such as Weill Cornell Medicine-Qatar and the Michael J. Fox Foundation. Headquartered in Seattle, Washington, and founded in 2016, the company advances proteomics to support breakthroughs in human health and medicine, particularly in Alzheimer's and other neurodegenerative areas.

CEO Mr. Sujal M. Patel · 127 employees · United States · https://www.nautilus.bio